Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...
Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...
Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...
Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...
VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...
Zymeworks Inc., a clinical-stage biotechnology company focused on developing innovative biotherapeutics for challenging diseases such as cancer, inflammation, and autoimmune disorders, has ...